Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Miltefosine and liposomal amphotericin B (AmBisome) are approved drugs for visceral
leishmaniasis. In this study both drugs will be given in a sequential manner. AmBisome will
be given on day 1, followed by Miltefosine for 14 days. Final Cure will be evaluated at six
months.
Phase:
Phase 2
Details
Lead Sponsor:
Banaras Hindu University
Collaborator:
Rajendra Memorial Research Institute of Medical Sciences
Treatments:
Amphotericin B Liposomal amphotericin B Miltefosine